top of page

GPCR News 

Post: Blog2_Post

Applying Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders with ...

April 2022


Applying Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders with Tim Dyer Addex Therapeutics


"Tim Dyer is the Co-Founder and CEO of Addex Therapeutics, which is focusing on the pharmacology known as allosteric modulation. This emerging class of small molecule drugs known as allosteric modulators is being explored for treating central nervous system and neurologic disorders, particularly movement disorders like dyskinesia associated with Parkinson's and dystonia. Addex did not invent allosteric modulation but is pioneering the screening technologies to find these difficult to locate molecules."


Read more at the source

#DrGPCR #GPCR #IndustryNews

0 views0 comments

Recent Posts

See All

August 2022 "THOUSAND OAKS, Calif. and SAN CARLOS, Calif., Aug. 4, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., (NASDAQ: CCXI), a biopharmaceutical company focused on orally admin